Assertio Holdings to be acquired by Zydus Worldwide in $23.50 per share cash deal

Assertio Holdings agreed to be acquired by Zydus Worldwide in a cash tender offer at $23.50 per share, implying an equity value of about $166.4 million and a small premium to the current $23.34 price. The deal ends the prior Garda Therapeutics process, with Zydus waiving a condition that Assertio repurchase and solicit consent on its 6.50% convertible notes due 2027. Completion remains subject to customary closing conditions, but the announcement is a clear takeover catalyst for ASRT shares.

Analysis

This is not a classic takeout arbitrage; it is a de-risking event in a microcap name that has already repriced for deal certainty. The spread is too tight to offer much standalone edge, so the real opportunity is in financing and optionality around the capital structure: the equity should behave like a short-duration cash instrument, while the convert embeds the more interesting displacement trade because its terms improve if the merger closes cleanly. The waiver on the note repurchase requirement also matters second-order: it reduces execution friction and signals the buyer is prioritizing speed over balance-sheet cleanup, which lowers the odds of a negotiated deterioration but leaves holders exposed to process risk.

The key catalyst window is days to weeks, not months. If the tender launch and SEC materials are delayed, the stock can gap wider on any incremental uncertainty because the current price leaves almost no cushion for regulatory or closing slippage. Conversely, if the bid is mechanically accepted, upside from here is capped, making the equity a poor long unless the investor has a specific view on a superior topping bid, which now looks less likely after the board’s selection process.

The contrarian angle is that the market may be underpricing how little convexity remains in the stock versus how much optionality still sits in the convert. In other words, the common has become a low-beta quasi-cash settlement claim, while the note may be the cleaner way to express deal completion versus disruption. The broader read-through for healthcare microcaps is that strategic buyers are willing to pay for hard-to-replicate assets, but once a board has run a process, the probability of a materially better bid falls sharply and the remaining return profile compresses fast.

Key Decisions for Investors

• Avoid fresh long ASRT common here; at a sub-1% deal spread, expected value is poor unless you have a view on a competing bid within 1-2 weeks.
• If eligible, rotate from ASRT common into the 6.50% 2027 converts as a relative-value hold through close; the note has cleaner downside protection if the transaction drags, with modest upside from improved conversion economics.
• For event-driven books, consider a small short-common vs. long-convert pair in ASRT for 2-6 weeks to capture the spread if settlement mechanics stay orderly; risk is process break or note-specific technicals.
• Set a tight alert on any SEC filing/tender-launch delay: if the offer does not commence on schedule, reduce exposure immediately because the equity can re-rate down 3-5% on timing slippage.
• Look for sympathy in other beaten-down healthcare microcaps with active strategic reviews; ASRT reinforces that cash bids are still clearing, but only after substantial prior rerating, so avoid chasing late-stage rumor names.